一分钟看懂
这是一项关于结直肠癌的不适用研究，登记的药物或干预包括Dissection of the No.253 lymph node；Omitting the dissection of the No.253 lymph node，当前状态为招募中。登记地点显示中国北京、上海、成都有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Dissection of the No.253 lymph node；Omitting the dissection of the No.253 lymph node · 不适用
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Peking Union Medical College Hospital · 北京
- China-Japan Friendship Hospital · 北京
- Beijing Cancer Hospital · 北京
- Chinese PLA General Hospital · 北京
- Cancer Hospital Chinese Academy of Medical Sciences · 北京
- Ruijin Hospital, Shanghai Jiaotong University School of Medicine · 上海
- Fudan University Shanghai Cancer Center · 上海
- West China Hospital Sichuan University · 成都
公开的入选条件
- 1. Patient age between 18-75 years.
- 2. Colonic biopsy pathology confirms adenocarcinoma.
- 3. The inferior margin of the primary tumor is ≤ 7 cm from the anal verge, as confirmed by colonoscopy and baseline imaging at initial diagnosis.
- 4. At initial treatment, imaging diagnoses the tumor T stage as less than or equal to 3.
- 5. At initial treatment, imaging diagnoses no enlarged lymph nodes at the root of the inferior mesenteric artery.
- 6. At initial treatment, imaging diagnoses the number of mesenteric metastatic lymph nodes as less than or equal to three.
- 7. Strong willingness for surgery and signed informed consent.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06146946；登记信息更新于 2026-09-15。